Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compassionate Use of AMX0035 for ALS
NCT04516096Phase 3Completed
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sodium phenylbutyrate in amyotrophic lateral sclerosis (ALS), sponsored by Amylyx Pharmaceuticals. Started Nov 2020; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04516096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04516096.